Cadrenal Therapeutics (CVKD) to Post Earnings on Monday

Cadrenal Therapeutics (NASDAQ:CVKD) will likely be issuing its Q2 2026 results before the market opens on Monday, August 10th. Analysts expect Cadrenal Therapeutics to post earnings of ($1.42) per share for the quarter. Investors can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 14, 2026 at 9:30 AM ET.

Cadrenal Therapeutics (NASDAQ:CVKD) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.51) by $0.47. On average, analysts expect Cadrenal Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Cadrenal Therapeutics Stock Performance

Shares of NASDAQ:CVKD opened at $2.01 on Monday. The company has a 50-day moving average price of $3.27 and a 200-day moving average price of $5.21. The company has a market cap of $6.87 million, a price-to-earnings ratio of -0.36 and a beta of 1.84. Cadrenal Therapeutics has a 12 month low of $1.86 and a 12 month high of $14.64.

Insider Buying and Selling at Cadrenal Therapeutics

In other news, CEO Quang X. Pham sold 9,029 shares of Cadrenal Therapeutics stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $3.05, for a total transaction of $27,538.45. Following the sale, the chief executive officer owned 105,989 shares of the company’s stock, valued at approximately $323,266.45. The trade was a 7.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 97,500 shares of company stock worth $388,290. Insiders own 26.09% of the company’s stock.

Institutional Trading of Cadrenal Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of CVKD. Geode Capital Management LLC grew its holdings in shares of Cadrenal Therapeutics by 14.3% during the 4th quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock worth $98,000 after acquiring an additional 1,818 shares during the period. JPMorgan Chase & Co. bought a new position in shares of Cadrenal Therapeutics in the 3rd quarter worth approximately $103,000. DRW Securities LLC purchased a new position in shares of Cadrenal Therapeutics in the 4th quarter valued at approximately $171,000. Finally, Citadel Advisors LLC purchased a new position in shares of Cadrenal Therapeutics in the 3rd quarter valued at approximately $274,000. 7.92% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have commented on CVKD shares. Wall Street Zen raised Cadrenal Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings reissued a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research note on Friday, July 17th. Finally, HC Wainwright decreased their target price on Cadrenal Therapeutics from $32.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday, April 7th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $13.00.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.